NCT06023758招募中2 期
A Multicenter II Study to Compare KN026 and KN046 Versus Oxaliplatin, Capecitabine Combined KN026 and KN046 in Patients With HER2-positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
Peking University1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2023年9月22日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- pCR rate
研究概览
简要总结
This is a multicenter II study to compare KN026 and KN046 versus Oxaliplatin, Capecitabine combined KN026 and KN046 in patients with HER2-positive locally advanced resectable gastric cancer or gastroesophageal junction adenocarcinoma.
详细描述
KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, resulting in dual HER2 signaling blockade.KN046 is a PD-L1 - CTLA-4 bispecific antibody. The trial consists of two groups. All subjects will be treated with KN026 at 30 mg/kg Q3W in combination with KN046 at 5 mg/kg Q3W in Group 1. If the statistical hypothesis is not met in Group 1, patients will be enrolled in Group 2. Patients in group 2 will receive KN026+KN046+XELOX.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject can understand the informed consent, voluntarily participate and sign the informed consent ;
- •Subjects are older than or equal to 18 years old and younger than or equal to 75 years old on the day of signing the informed consent；
- •Histologically or cytologically confirmed, locally advanced HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.
- •ECOG score 0 or 1;
- •Left ventricular ejection fraction (LVEF) ≥ 50% at baseline as determined by either ECHO (preferred) or MUGA;
- •Liver function met the following criteria within 7 days prior to initial administration:
- •Total bilirubin ≤1.0x ULN (Gilbert's syndrome, or total bilirubin ≤1.5x ULN in liver metastases); Aminotransferase (ALT/AST) ≤1.5x ULN (liver metastatic subjects ≤3xULN); -Renal function within 7 days prior to initial administration: serum creatinine ≤1.5x ULN and serum creatinine clearance ≥60mL/min (according to Cockcroft-Gault Formula calculation);
- •Bone marrow function met the following criteria within 7 days prior to initial administration: Hemoglobin ≥90 g/L; Neutrophil absolute count ≥1.5 x 109/L; Platelet count ≥100x 109/L; INR or PT≤1.5x ULN, and aPTT≤ 1.5x ULN;
- •Life expectancy >3 months;
- •The subjects are able and willing to follow the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol
排除标准
- •Existence of other active malignant tumors within 5 years or at the same time. Plan to perform or have undergone an organ or bone marrow transplant. Myocardial infarction and poorly controlled arrhythmias occurred within 6 months prior to the first dose.
- •Existence of grade III - IV cardiac disorders defined by the NYHA or echocardiogram shows: LVEF (left ventricular ejection fraction) < 50%.
- •Human immunodeficiency virus (HIV) infection.
- •Patients with active tuberculosis.
- •Patient with previous or current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severely impaired lung function, etc.
- •Patients who have previously received other antibody/drug treatments for immune checkpoints, such as PD-1, PD-L1, and CTLA4 treatments.
- •Have diseases that may increase the risk of participating in the study and using the study medications, or other severe, acute, and chronic diseases and therefore are judged by the investigator to be unsuitable for clinical studies.
研究组 & 干预措施
KN026 combined with KN046
Experimental
KN026 combined with KN046
干预措施: KN026 (Drug)
KN026 combined with KN046
Experimental
KN026 combined with KN046
干预措施: KN046 (Drug)
KN026，KN046 and XELOX
Experimental
KN026，KN046 and XELOX
干预措施: KN026 (Drug)
KN026，KN046 and XELOX
Experimental
KN026，KN046 and XELOX
干预措施: KN046 (Drug)
KN026，KN046 and XELOX
Experimental
KN026，KN046 and XELOX
干预措施: XELOX (Drug)
结局指标
主要结局
pCR rate
时间窗: up to 2 years
Pathological complete response (pCR) rate (assessed by central pathology laboratory and the site)
次要结局
- Event-free survival (EFS)(from enrollment until firstly confirmed and recorded disease progression or death，assessed up to 3 years)
- Disease-free survival (DFS)(from the start of surgery to disease recurrence or death (for any reason)，assessed up to 3 years)
- overall survival (OS)(From date of randomization until the date of death from any cause, assessed up to 5 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Study of KN046 With Chemotherapy in First Line Advanced NSCLCNon-small Cell Lung CancerNCT04054531Jiangsu Alphamab Biopharmaceuticals Co., Ltd50
已完成
1 期
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerTriple-negative Breast CancerNCT03872791Jiangsu Alphamab Biopharmaceuticals Co., Ltd52
Unknown
2 期
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast CancerBreast CancerNCT04881929Jiangsu Alphamab Biopharmaceuticals Co., Ltd30
已完成
2 期
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02434744Response Pharmaceuticals121
终止
2 期
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerMetastatic Kidney CarcinomaRecurrent Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7NCT01239342National Cancer Institute (NCI)43